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The liver maintains glucose and lipid homeostasis by
adapting its metabolic activity to the energy needs
of the organism. Communication between hepato-
cytes and extracellular environment via endocytosis
is key to such homeostasis. Here, we addressed
the question of whether endosomes are required
for gluconeogenic gene expression. We took advan-
tage of the loss of endosomes in the mouse liver
upon Rab5 silencing. Strikingly, we found hepato-
megaly and severe metabolic defects such as hypo-
glycemia, hypercholesterolemia, hyperlipidemia, and
glycogen accumulation that phenocopied those
found in von Gierke’s disease, a glucose-6-phospha-
tase (G6Pase) deficiency. G6Pase deficiency alone
can account for the reduction in hepatic glucose
output and glycogen accumulation as determined by
mathematical modeling. Interestingly, we uncovered
functional alterations in the transcription factors,
which regulateG6Pase expression.Our data highlight
a requirement of Rab5 and the endosomal system for
the regulation of gluconeogenic gene expression that
has important implications for metabolic diseases.
INTRODUCTION
The liver plays an essential role in the metabolic adaptation to
nutrients through processes such as gluconeogenesis, glycogen-
olysis, lipogenesis, and fatty acid oxidation that are under the con-
trol of glucagon and insulin. In the absorptive state, when high
glucose levels induce insulin secretion, anabolic pathways, such884 Cell Reports 11, 884–892, May 12, 2015 ª2015 The Authorsas glycogen production and lipogenesis are activated, whereas
catabolic processes are inhibited. In the fasted state, when
glucagon is elevated relative to insulin, fatty acid oxidation, glyco-
genolysis, and gluconeogenesis are induced to maintain blood
glucose homeostasis (Lin and Accili, 2011). Dysfunction of
glucose production leads to severe metabolic diseases. The
most common pathology is associated with insulin resistance,
which contributes to type 2 diabetes and themetabolic syndrome
(Lin and Accili, 2011). In this disease, insulin fails to exert an inhib-
itory role on gluconeogenesis. Mutations in genes involved in
gluconeogenesis can cause glycogen storage diseases with
marked alterations in glucose homeostasis. For example, von
Gierke’s disease, the glycogen storage disease type Ia (GSD-Ia),
is an autosomal recessive disorder caused by a deficiency of
glucose-6-phosphatase (G6Pase) and characterized by hypogly-
cemia, abnormal glycogen accumulations (glycogenesis), hepa-
tomegaly, and hyperlipidemia, among others (Chou et al., 2010).
Glucose homeostasis is regulated by endocytosis. Endocy-
tosis is an essential mechanism for the uptake and signal trans-
duction of growth factors and hormones (Sorkin and vonZastrow,
2009) but also for regulating metabolic activities, by changing the
expression of hormone receptors and nutrient transporters on
the cell surface. For example, in fat and muscle cells, the amount
of internalized glucose can be modulated by varying the rates
of endo- and exocytosis of the insulin-responsive glucose trans-
porter, GLUT4 (Antonescu et al., 2014). Endocytosis governs the
clearance of low-density-lipoproteins (LDLs) from the circulation
especially in the liver, where mutations in this process cause hy-
percholesterolemia (Koivisto et al., 2001). New evidence
suggests that the endo-lysosomal system is also involved in the
regulation of metabolic gene transcription. For example, the
transcription factor EB (TFEB) translocates from lysosomes to
the nucleus in response to starvation and activates genes in-
volved in lysosomal biogenesis, autophagy, and lipid metabolism
(Settembre et al., 2013). Conversely, metabolic activities also
regulate endocytosis, since knockdown of metabolic genes in a
genome-wide RNAi screen had dramatic effects on endocytic
trafficking (Collinet et al., 2010). Together, these findings suggest
that endocytosis and metabolism are functionally coupled.
Understanding the role of the endocytic system in the regula-
tion of metabolism would require molecular perturbations
capable of ablating the function of endosomes. The small
GTPase Rab5 regulates the membrane assembly of a multi-pro-
tein machinery conferring early endosome identity and function,
such as endosome tethering, fusion, and motility (Wandinger-
Ness and Zerial, 2014). Remarkably, liver-specific knockdown
of Rab5 by RNAi in mice causes a massive depletion of
endosomes and lysosomes, indicating that it is necessary for
endosome biogenesis (Zeigerer et al., 2012). Interestingly, ultra-
structural analysis of liver sections also revealed a strong accu-
mulation of glycogen granules and lipid droplets in the liver,
raising the question of why depletion of Rab5 and, consequently,
of the endosomal system causes severe alterations in hepatocel-
lular glucose and lipid metabolism. In the present study, we ad-
dressed this question through a systems biology approach.
RESULTS
Rab5 Is Essential for Lipid and Glucose Metabolism in
the Liver
The three Rab5 isoforms were silenced in mouse liver by RNAi
through tail vein injection of lipid nanoparticles (LNPs) containing
small interfering RNAs (siRNAs) (against Rab5a,b,c or luciferase),
as previously described (Zeigerer et al., 2012). Five days after in-
jection, when the reduction in endosome number in Rab5 knock-
down (Rab5KD) livers is maximal (Zeigerer et al., 2012), mice
were starved for 6 hr, their liver extracted and analyzed by tran-
scriptomics, proteomics, and lipidomics. The transcriptomics
analysis was performed by microarray and RNA sequencing
(RNA-seq). Comparison of the hits from the differentially ex-
pressed genes (DEG) in both data sets revealed 451 common
DEG, resulting in 77% overlap (RNA-seq to microarray), showing
a high Spearman correlation (Figures S1A and S1B; Table S1).
Thedata setwassplit into 328up- and123downregulated genes,
which were considered separately for pathway enrichment anal-
ysis (Table S1). Strikingly, we observed severe alterations in
genes involved in metabolic pathways. Among the upregulated
genes, there was a significant enrichment for genes associated
with cell-cycle and steroid biosynthesis, suggesting that loss of
Rab5 affects cell proliferation and lipid metabolism (Figure S1C).
The upregulation of steroid biosynthesis can be explained by a
compensatory increase consequent to the block of LDL internal-
ization (Brown andGoldstein, 2009; Zeigerer et al., 2012). For the
downregulatedgenes,metabolismof xenobiotics bycytochrome
p450, fatty acid, amino acid metabolism, and glucose meta-
bolism were significantly affected (Figure S1D). These data
show that Rab5 depletion induces alterations in gene expression
for specific metabolic pathways in the liver.
For quantitative proteomics, control and Rab5KD liver tissues
were subjected to liquid chromatography-tandem mass spec-
trometry (LC-MS/MS), and a combined analysis of the spectra
from all samples resulted in the identification of 8,000 proteinsat a false discovery rate (FDR) of 1%. Using the label-free quan-
tification algorithm inMaxQuant, wemeasured the abundance of
5,800 proteins in at least one pairwise comparison (Table S2).
We detected 980 differentially expressed proteins (DEPs), of
which 553were up- and 427 downregulated compared to control
t test (p < 0.05) (Table S2). Consistent with the transcriptomics
data, most proteins were again involved in cellular metabolism
(Figure 1).
Next, we subjected the DEP to pathway enrichment analysis
using KEGG (Figures 1A and 1B; Table S2) and a topological
model of central metabolism (Figure S2A). In agreement with
the transcriptomics, proteins involved in steroid biosynthesis
were upregulated. Strikingly, most metabolic pathways, such as
b-oxidation, fatty acid, andglucosemetabolism,etc.,weredown-
regulated (Figure 1; TableS2).Comparisonof theproteomicswith
the transcriptomics data sets revealed 88 common genes/
proteins (Figure S1E; Table S3). Most hits were well correlated
(Figure S1F), suggesting a regulation at the mRNA level. These
candidates were again enriched in metabolic pathways with an
upregulation in steroid and terpenoid backbone biosynthesis
and a downregulation of fatty acid and amino acid metabolism
(Figures S1G and S1H). Taken together, these data indicate that
the liver responds to Rab5KD by boosting the pathways for ste-
roidbiosynthesiswhile reducingglucose andenergymetabolism.
The levels of lipids in the liver and serum were determined by
shotgun lipidomics. Consistent with transcriptomics and prote-
omics, we found a 2-fold enrichment of cholesterol and choles-
terol ester (CE) in liver tissue of Rab5KDmice, with all CE species
increased (Figure 1C). The excess of CE could explain in part the
increase in lipid droplets (Miller and Bose, 2011) observed by EM
upon Rab5KD (Zeigerer et al., 2012). In addition, we could not
detect an induction of autophagosomes (data not shown),
consistent with the loss of endosomes and lysosomes (Lamb
et al., 2013). This implies that also lipophagy may be inhibited
(Dong and Czaja, 2011), thus contributing to the accumulation
of lipid droplets.
Interestingly, lipidomics analysis of sera from Rab5KD animals
revealed a 2- to 5-fold increase in all major lipid classes
(Figure 1D), leading to an induction of hyperlipidemia and hyper-
cholesterolemia at 5 days after LNP injection. Importantly, this
increase was reversible and serum lipids returned back to
normal levels after recovery of the endosomal system at
10 days after injection (Figure 1D; Zeigerer et al., 2012). Alto-
gether, Rab5 depletion causes severe changes in the expression
of metabolic pathways associated with steroid biosynthesis,
fatty acid, amino acid, and glucose metabolism.
Rab5 Depletion Causes Hepatomegaly
At 5 days post-injection, Rab5KD animals were similar in weight
(Figure S3A) but exhibited an increase in liver size (Figure 2A),
raising the liver/body weight ratio from 5% to 7% (Figure 2B).
Interestingly, the induction of hepatomegaly coincided with the
accumulation of glycogen (Zeigerer et al., 2012), suggesting that
the two events may be linked. Hepatomegaly could either be
caused by an increase in the size or the number of hepatocytes,
or both. To distinguish between these possibilities, we performed
a morphological analysis of liver sections and measured a 20%–
30% increase in hepatocyte area in vivo (Figures S3B and S3C).Cell Reports 11, 884–892, May 12, 2015 ª2015 The Authors 885
Figure 1. Proteomics and Lipidomics of
Rab5KD Livers Reveal Alterations in Meta-
bolism
(A–C) Significantly enriched KEGG pathways of
up- (A) and downregulated (B) proteins. (C)
Representative profiles of all lipid classes
(normalized to phospholipids) (*p < 0.05, n = 4
mice per condition). Inset: lipid species of
cholesterol esters (mean ± SEM).
(D) Time course of lipid profiles in serum (n = 4
mice per condition, mean ± SEM).In addition, applyingproteome ruler for theproteomicsdata set re-
vealed a 1.4-fold increase in the total protein content per cell and
cell volume (Figures S3D and S3E), in agreement with the image
analysis. Such an expansion in cell volume agrees with the obser-
vation that glycogen accumulation causes swelling of hepato-
cytes (Froissart et al., 2011). However, H&E staining revealed
also amild increase in theproliferation index inRab5KD livers (Fig-886 Cell Reports 11, 884–892, May 12, 2015 ª2015 The Authorsure S3F) consistent with our transcriptom-
ics analysis. Altogether, these data sug-
gest that the hepatomegaly is accounted
by an increase in hepatocytes volume
and a mild increase in their number.
Rab5 Knockdown Induces
Hypoglycemia
The alterations in glycolysis/gluconeo-
genesis together with the accumulation
of glycogen granules suggest a connec-
tion between endosomes and the regula-
tion of sugar metabolism. We therefore
undertook a detailed analysis of the ef-
fects of Rab5 depletion on glucose ho-
meostasis. We found a 30% reduction in
fasting blood glucose levels compared
to control at 5 days post-injection (Fig-
ure 2C). Surprisingly, no alterations in
serum levels of insulin and glucagon
were observed that could account for
thedecrease in blood glucose (Figure 2D),
arguing for a more direct effect of Rab5
on glucose homeostasis in the liver. Inter-
estingly, upon endosomal recovery at
10 days post-injection (Zeigerer et al.,
2012), similar to liver size, blood glucose
levels returned to normal (Figures 2B
and 2C), suggesting that hypoglycemia
and hepatomegaly correlate with the
loss of Rab5 and endosomes.
Rab5KD Phenocopies the Loss of
G6Pase in von Gierke’s Disease
The accumulation of glycogen granules
and lipid droplets, hypoglycemia, hepa-
tomegaly, hypercholesterolemia, and
hyperlipidemia observed upon Rab5KDstrikingly resemble the alterations in von Gierke’s disease
(glycogen-storage disease type Ia) (Chou et al., 2010). von
Gierke’s disease is caused by a deficiency of G6Pase, the major
enzyme controlling glucose release by the liver via glycogenol-
ysis and gluconeogenesis. Therefore, we analyzed the G6Pase
mRNA levels after 5 days post-injection. Strikingly, the expres-
sion of G6Pase was almost ablated (Figure 2E and Table S1).
Figure 2. Metabolic Effects of Rab5KD
(A and B) Liver size (day 5) (A) and liver/body (B)
weight ratio (time course) for 6-hr-fasted mice.
(C) Time course of blood glucose levels for C57BL/
6N and in db/db mice.
(D) Insulin and glucagon levels of five independent
experiments normalized to control.
(E) Relative expression of G6Pase (time course)
and Pepck in livers of C57BL/6N, db/dbmice (day
5), and in primary hepatocytes.
(F and G) (F) Liver glycogen content and (G) py-
ruvate tolerance test (2 mg/kg) at day 5.
Representative experiments shown for (A)–(C) and
(E)–(G); four mice per condition used for (B)–(G);
mean ±SEM; #p > 0.1, *p < 0.05, **p < 0.001, ***p <
0.0001.Since Rab5-depleted animals fail to mobilize their glycogen
stores (Zeigerer et al., 2012), we quantified the glycogen in the
liver and measured a 2-3-fold increase in glycogen levels in 6-
hr-starved Rab5KD mice (Figure 2F). Glycogen levels are regu-
lated by a balance of synthesis, via glycogen synthase (GS),
and breakdown, through glycogen phosphorylase (GP), both
regulated by phosphorylation. In addition, GS is also allosteri-
cally activated by glucose-6-phosphate (G6P) (von Wilamo-
witz-Moellendorff et al., 2013). We detected only a slight
increase in GS (p = 0.06) but not GP phosphorylation in Rab5KD
livers compared to control (Figures S4A and S4B). However, the
G6P levels were increased over 2-fold (Figure S4C). Such in-
crease is expected to activate GS, thus explaining the enhanced
glycogen deposition. These data suggest that the glycogen stor-
age phenotype is caused by the reduction in G6Pase, just as inCell Reports 11, 884–8von Gierke’s disease (Cori and Cori,
1952), leading to the accumulation of
G6P and activation of GS.
To directly test whether gluconeogen-
esis was inhibited, pyruvate tolerance
tests were performed in control and
Rab5KD mice. Rab5KD almost com-
pletely abolished glucose production by
the liver (Figure 2G). This is consistent
with transcriptomics and quantitative
PCR (qPCR) analysis, which revealed a
strong reduction in Phosphoenolpyruvate
kinase (Pepck1), another rate-limiting
enzyme for gluconeogenesis (Table S1
and Figure 2C). Importantly, after
10 days post-injection when the levels
of Rab5 and the endosomal pathway
recovered (Zeigerer et al., 2012), the
expression of G6Pase was restored (Fig-
ure 2E), leading to normal glycemia and
receding the metabolic phenotypes (Fig-
ures 2B, 2C, and 2E).
Although Rab5 was silenced specif-
ically in the liver (Zeigerer et al., 2012),
the reduction in G6Pase and Pepck
expression could be triggered by endo-crine signals from other organs. To rule out this possibility, we
silenced Rab5 in isolated primary hepatocytes. Once again, we
observed a strong decrease in G6Pase and Pepck1 expression
(Figure 2E), arguing that it is mediated by a hepatocyte-autono-
mous rather than a systemic effect. Taken together, these data
suggest that the expression of G6Pase as well as other gluco-
neogenic genes is subjected to regulation by the endosomal
system.
Mathematical Modeling and Simulations Suggest that
the Block in Glucose Output and Accumulation of
Glycogen Can Be Explained by Loss of G6Pase in
Rab5KD Liver
How does G6Pase loss affect glucose output and glycogen pro-
duction? We applied a mathematical kinetic model of hepatic92, May 12, 2015 ª2015 The Authors 887
Figure 3. MathematicalModelingofGlucose
Fluxes and Glycogen Accumulation
(A and B) Model simulation of fluxes for glycolysis
(PFK1, FBP1) (A) and gluconeogenesis (PK, PC) (B)
for control (black), G6Pase knockout (blue), and the
Rab5KD (green) livers.
(C) Simulation of glycogen dynamics in mouse
livers during re-feeding and fasting.glucose metabolism (Figure S2A) that takes into account meta-
bolic regulation through substrates and allosteric effectors,
reversible phosphorylation controlled by plasma insulin and
glucagon, as well as changes in the amount of metabolic en-
zymes through variable gene expression. Model parameters
(Km and Ki values) were obtained from literature. Vmax values
for the reference state were calibrated to match physiological
metabolite concentrations (S.B., H.-G.H., and N.B., unpublished
data). Relative changes in protein levels of 24 proteins (Table S4)
upon Rab5KD measured by proteomics were taken to scale the
Vmax values for the Rab5KD.
Glycolytic fluxes through PFK1 and PK and gluconeogenic
fluxes through FBP1 and PC simulated with the model are de-
picted (Figures 3A and 3B). G6Pase knockout (KO) (blue) in-
creases the glycolytic flux and decreases the gluconeogenic
flux compared to control (fasted hepatocyte, black line). The pro-
teome changes upon Rab5KD (green) decrease the futile fluxes
between the opposing reactions (PFK1/FBP1 and PK/PC) in
glycolysis and gluconeogenesis. Flux through gluconeogenesis
was stronger affected by Rab5KD than by complete KO of
G6Pase alone, consistent with the reduction in additional rate-888 Cell Reports 11, 884–892, May 12, 2015 ª2015 The Authorslimiting genes of gluconeogenesis (Table
S1). The model simulations further sup-
port the suggestion that the reduction in
G6Pase expression is sufficient to explain
the decrease of glucose production upon
Rab5KD.
To simulate glycogen dynamics asso-
ciated with the fasting-refeeding-fasting
cycle, we applied the same model to
compare control, G6Pase KO, and
Rab5KD (Figure 3C). Initial fasting and re-
feeding (gray-shaded area) were simu-
lated by blood glucose levels of 4 and
10 mM, respectively. Fluxes for glucoki-
nase (GK), G6PPase (G6PP), glucose
phosphate isomerase (GPI) (represent-
ing glycolytic/glyconeogenic flux), phos-
phoglucomutase (PGM) (representing
glycogen synthesis/glycogen degrada-
tion), and glucose transporter (GlcT) are
shown in Figure S2B. Glycogen is synthe-
sized during the refeeding period and
degraded in the fasting period in all con-
ditions. Higher glycogen content leads
to an increase in the flux through GP re-
sulting in production of G6P. G6P can
either be metabolized through glycolysisor converted to glucose via G6Pase. The loss of G6Pase in von
Gierke’s disease and upon Rab5KD leads to (1) a higher flux
through glycolysis shown by GPI, (2) a rerouting back to
glycogen production (through higher GS flux), and (3) to the
accumulation of G6P and glycogen (Cori and Cori, 1952; Figures
S4C and 2F). The simultaneous accumulation of G6P and
glycogen lead to an increase in the flux through GS and GP
without necessarily modifying their phosphorylation state. Inter-
estingly, the proteome changes upon Rab5KD (Tables S2; Table
S4) result only in a partial compensation causing higher G6P and
glycogen content compared to control, as observed experimen-
tally. Altogether, the model simulations support our conclusion
that the reduction of G6Pase upon Rab5KD is sufficient to
explain the accumulation of glycogen.
The Rab5KD Liver Fails to Induce Gluconeogenic Gene
Expression due to an Inhibitory Effect on CREB,
ChREBP, and FoxO1 Function
The expression of G6Pase and Pepck1 is under the opposite
control of insulin and glucagon (Lin and Accili, 2011). As
the levels of insulin and glucagon did not vary significantly
Figure 4. G6Pase Reduction Is Independent
of Insulin Signaling
(A and C) Representative western blots for Akt,
GSK3b (A and C), and p-S6-RP (A) in livers after 6-
hr fast (A) and after insulin stimulation (0.75U/kg,
5 min) (C).
(B) Quantification of five independent experiments
from (A).
(D) Quantification of representative experiment
from (C) (mean ± SEM); #p > 0.1.(Figure 2D), we inspected their signaling activity. First, we
analyzed the activation of Akt and its downstream kinases. We
observed a 20% increase in the p-Akt/Akt ratio in liver lysates
from Rab5KD animals compared to control; however, this in-
crease was not statistically significant (Figures 4A and 4B).
Furthermore, the levels of the downstream kinase GSK3b were
increased, but its phospho/total ratio and that of P-S6-RP
were unchanged (Figures 4A and 4B). In addition, the response
to insulin stimulation in vivo was not altered, as Rab5KD animals
showed a similar activation of Akt and its downstream kinase
GSK3b (Figures 4C and 4D). Occasionally, animals exhibited a
stronger increase in p-Akt levels (up to 200%) in the basal state.
However, since such an increase was not consistent between
animals, it cannot be the sole mechanism underlying the loss
of G6Pase and Pepck1.
We then verified that glucagon signaling was induced effi-
ciently in response to hypoglycemia. Glucagon leads to an in-
crease in cyclic AMP (cAMP) that activates protein kinase A
(PKA), which, in turn, phosphorylates CREB, a key transcription
factor controlling gluconeogenic gene expression (Altarejos and
Montminy, 2011). The basal cAMP levels and PKA activity were
increased in the liver of Rab5KD animals compared to control
(Figures 5A and 5B). As expected, phospho-CREB was also
increased (Figures 5C and 5D), suggesting that the liver re-
sponded normally to glucagon.
We next inspected the transcription factors responsible for
G6Pase gene expression, CREB, PGC1a, ChREBP, and FoxO1
using a combination of qPCR, western blot, and quantitative
immunofluorescencemicroscopy analysis. Surprisingly, although
the levels of CREB were increased, the expression of its targetCell Reports 11, 884–8PGC1a (Lin et al., 2005) was repressed
(Figure 5E). In addition, ChREBP (Ma
et al., 2006) was reduced by 50% (Fig-
ure 5E). FoxO1 is mainly negatively regu-
lated by phosphorylation (Matsumoto
et al., 2007). FoxO1 showed a modest
(20%) decrease in gene expression but a
100% increase in phospho-FoxO1, sug-
gesting a reduction in activity (Figures
5C–5E).
To verify whether the translocation
of CREB, FoxO1, and phospho-FoxO1
between the cytoplasm and nucleus
occurred normally, we visualized their
intracellular localization in primary hepa-
tocytes and mouse liver upon Rab5KD.CREB levels were unchanged and accumulated in the nucleus
upon Rab5 depletion in vitro and in vivo (Figures S5A–S5D).
However, total FoxO1 remained largely cytoplasmic (Figures
S5A and S5C) with a modest decrease in protein levels (Fig-
ure S5B). This is consistent with a strong increase in the levels
of Akt-dependent phospho-Ser256-FoxO1 (Figures 5F, 5G,
and S5D) in primary hepatocytes and mouse liver. Therefore,
although the reduction in FoxO1 expression is modest, the
increased phosphorylation and lack of nuclear translocation
argue that its function is severely impaired. These data sug-
gest that endosomes exert a regulatory role on the expression,
activity, or nuclear translocation of the transcription factors for
the gluconeogenic genes.
Rab5KD Rescues Hyperglycemia in Diabetic db/db Mice
Patients with type 2 diabetes fail to respond to insulin, a defi-
ciency known as insulin resistance. Consequently, the liver en-
hances gluconeogenesis, contributing to hyperglycemia. If the
regulation of gluconeogenic gene expression via endosomes
were part of this mechanism, silencing Rab5 in the liver might
rescue the hyperglycemia in diabetes. To test this possibility,
we downregulated Rab5 in a mouse model of type 2 diabetes
(db/db; LepR KO) and tested the effects on blood glucose and
gluconeogenic gene expression in the liver of 10-week-old db/
db mice. Strikingly, depletion of Rab5 5 days post-injection
led to a 50% decrease in blood glucose, suggesting that
loss of endosomes improved glucose homeostasis specifically
in db/db mice (Figure 2C). Interestingly, the expression of
G6Pase and Pepck1 was strongly reduced upon Rab5 loss
in livers of db/db mice (Figure 2E) supporting an involvement92, May 12, 2015 ª2015 The Authors 889
Figure 5. G6Pase Transcription Factor Al-
terations upon Rab5KD
(A–E) cAMP amount (A), PKA activity (B), western
blots of p-CREB and p-FoxO1 (C), and quantifi-
cation thereof (E), relative mRNA expression of
CREB, FoxO1, PGC1a, and ChREBP (E) from
livers of 6-hr-starved control and Rab5KD mice
(representative experiment shown; n = 4 mice per
condition).
(F and G) (F) Representative confocal images
(maximal projections of three merged middle
sections) of primary hepatocytes stained with p-
FoxO1 plus DAPI and (G) quantification thereof
within cellular masks by QMPIA.
Scale bar, 20 mm (mean ± SEM) *p < 0.05, **p <
0.01, ***p < 0.0001.of endosomes in the regulation of gluconeogenic gene
expression.
DISCUSSION
In this study, we have uncovered a requirement of Rab5 and the
endosomal system for the regulation of hepatic metabolism.
Depletion of Rab5 boosts steroid biosynthesis while blocking890 Cell Reports 11, 884–892, May 12, 2015 ª2015 The Authorsgluconeogenesis. The induction of ste-
roid biosynthesis is an expected con-
sequence to the inhibition of LDL endo-
cytosis (Brown and Goldstein, 2009;
Zeigerer et al., 2012). Much more unex-
pected are the effects on glucose meta-
bolism. The accumulation of glycogen
granules, the increase in liver size, and
the reduction in G6Pase gene expression
all point at a striking similarity with the von
Gierke’s disease (Chou et al., 2010). The
loss of G6Pase in von Gierke’s disease
appears to be sufficient to induce all
the consequent metabolic abnormalities,
e.g., accumulation of glycogen (Cori and
Cori, 1952), hepatomegaly (Froissart
et al., 2011), as well as hypercholester-
olemia and hyperlipidemia (Bandsma
et al., 2002). Mathematical kinetic
modeling and simulation of hepatic
glucose metabolism suggest that the
reduction in G6Pase expression alone
can explain the marked decrease in
glucose production upon Rab5KD.
Rab5 may exert its function through its
signaling effectors (Christoforidis et al.,
1999; Schenck et al., 2008; Shin et al.,
2005). However, we favor the interpreta-
tion that the metabolic alterations are
the consequence of the loss of endo-
somes and lysosomes. First, the Rab5
signaling effectors are localized to endo-
somes (Schenck et al., 2008). Second,the metabolic alterations remarkably correlate with the depletion
of endosomal compartments. Third, lysosomes play an impor-
tant role in glycogenolysis (see below). Another indication of
such a regulation is that Rab5 depletion was sufficient to over-
come the insulin resistant phenotype of diabetic mice.
Interestingly, a functional genomics screen revealed that
the endosomal system is modulated by a number of metabolic
pathways, including glycolysis, gluconeogenesis, and steroid
biosynthesis (Collinet et al., 2010). This argues that the functional
relationship between metabolism and endocytosis is bi-direc-
tional. Such a relationship goes beyond the classical view that
endocytosis regulates the surface expression of nutrient sensors
and transporters, e.g., GLUT4 (Antonescu et al., 2014). In our
study, the decrease of gluconeogenic gene expression and
occurrence of hypoglycemia upon Rab5KD cannot be explained
solely by the 30% reduction of GLUT2 observed by proteomics.
Insulin signaling was also not reproducibly affected.
Clearly, endocytosis is a key cellular process that, when per-
turbed, could have multiple direct or indirect effects on meta-
bolism. Among the many possible interpretations, one is that
endosomes could exert a regulatory role on the transcription fac-
tors responsible for gluconeogenic gene expression. We found
that loss of G6Pase upon Rab5KD is due to impairment in the
transcription factors regulating its expression. CREB was phos-
phorylated and translocated to the nucleus upon Rab5 depletion
but failed to induce the expression of its downstream target
PGC1a. The levels of ChREBP were reduced, and the nuclear
translocation of FoxO1 was inhibited, while its phosphorylation
increased. These results suggest that endosomes are directly
or indirectly necessary for the activity (CREB), expression
(ChREBP), and phosphorylation (FoxO1) of the transcription fac-
tors for G6Pase expression. One possibility is that they could
interact with Rab5 on the endosomal membrane, or through
intermediary molecules. Endosomes could provide a scaffold
for the transport toward the nucleus, as shown for CREB during
the retrograde transport from the growth cone to the cell body in
neurons (Cox et al., 2008), or for regulating their phosphorylation
state, as they regulate signal transduction (Sorkin and von Zas-
trow, 2009). Akt phosphorylates FoxO proteins leading to their
association with 14-3-3 and retention in the cytosol (Obsil and
Obsilova, 2008). Addressing this question requires the develop-
ment of new tools to detect the transcription factors intracellu-
larly and follow how signals are transmitted from the endosomes
to the kinases and phosphatases controlling their activity.
The functional connection between the endosomal system
and metabolism is exemplified by the Target of rapamycin
mTOR-TFEB pathway. The serine/threonine kinase mTOR is
localized to lysosomes and responds to nutrients, growth fac-
tors, bioenergetic needs, and cellular stress (Laplante and
Sabatini, 2012; Polak and Hall, 2009). When nutrients are avail-
able, mTORC1 phosphorylates the transcription factor TFEB
and inhibits its activity, whereas under starvation TFEB translo-
cates to the nucleus and induces the CLEAR transcriptional
network required for lysosomal biogenesis, autophagy, and lipid
catabolism (Settembre et al., 2013). Despite the severe loss of
endosomes and lysosomes upon Rab5KD, we did not observe
a significant induction of autophagy or TFEB activation. We
found only 13 genes of theCLEAR network that are transcription-
ally affected, 12 of them being upregulated upon Rab5KD. These
results make it unlikely that the mechanism by which Rab5KD
leads to the metabolic changes is TFEB dependent. Further-
more, we did not observe an induction of autophagosomes
probably due to the loss of endosomes and lysosomes,
which are necessary for their biogenesis (Lamb et al., 2013).
The disturbed response to starvation could therefore add to
the observed phenotypes. Clearance of intracellular lipids vialipophagy is probably perturbed, contributing to the accumula-
tion of lipid droplets. In addition, lysosomes have been impli-
cated in the breakdown of glycogen granules (Dong and Czaja,
2011), further substantiating the lack of glycogenolysis.
It is likely that endosomal regulation of metabolic activities is
not restricted to the liver but plays amore general role in different
tissues. Dysfunctions of the endosomal system could play a
regulatory role also in the development of metabolic diseases
such as hepatic insulin resistance. On the other hand, pharma-
cological modulation of selective components of the endosomal
system could be a possible strategy for therapeutic intervention.
Our results showing that depletion of Rab5 reduces blood
glucose levels in a mouse model of type 2 diabetes provide a
proof of principle for such an approach.
EXPERIMENTAL PROCEDURES
Animals
Animal studies were conducted in accordance with German animal welfare
legislation and in pathogen-free conditions in the animal facility of the MPI-
CBG, Dresden, Germany. Protocols were approved by the Institutional Animal
Welfare Officer (Tierschutzbeauftragter), and necessary licenses were ob-
tained from the regional Ethical Commission for Animal Experimentation of
Dresden, Germany (Tierversuchskommission, Landesdirektion Dresden).
Proteomics
Liver tissueswere processedaccording to the FASPmethod and separated us-
ing strong anion exchange (Sharma et al., 2014). MS analysis of resulting pep-
tides was performed by Q-Exactive mass spectrometer coupled on-line to a
nanoflowUHPLC instrument (ThermoFisherScientific). Spectrawere searched
against the Uniprot FASTA database using MaxQuant (Cox and Mann, 2008),
version 1.4.1.6. An FDR < 0.01 for proteins and peptides was required. Prote-
ome quantification was performed using LFQ algorithm (Cox et al., 2014).
Shotgun Lipidomics
Lipids were extracted frommouse liver and plasma by a modified Folch proto-
col (Folch et al., 1957) and analyzed by shotgun mass spectrometry (Schuh-
mann et al., 2012). Molecular species of 15 lipid classes were identified and
quantified by LipidXplorer software (Herzog et al., 2011).
Glucose Flux Modeling
The mathematical kinetic model comprises the pathways of glycolysis/gluco-
neogenesis and glycogen synthesis/glycogenolysis. Inputs are the external
glucose and insulin and glucagon concentrations as well as protein abun-
dances. Relative protein abundances are mapped as changes in Vmax values
on the respective reactions. Simulations were performed for varying external
glucose concentration between 3 and 15 mM. For the simulation of the
Rab5KD condition, a total knockout of G6Pase was assumed.
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